Atea Pharmaceuticals, Inc.

Atea Pharmaceuticals, Inc. reported a net loss of $158.3 million for fiscal year 2025, an improvement from a net loss of $193.0 million in the prior year. The company's operating expenses decreased to $180.9 million from $193.0 million, driven by reduced research and development costs. Atea remains a clinical-stage biopharmaceutical company with no commercial revenue, focusing its resources on the late-stage development of its lead HCV product candidate, the regimen of bemnifosbuvir and ruzasvir. The company's financial position is supported by $95.7 million in cash and cash equivalents and $206.1 million in marketable securities, with total assets of $315.2 million and stockholders' equity of $275.4 million as of December 31, 2025. Net cash used in operating activities was $132.0 million.

Key Takeaways